These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1473342)

  • 1. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics.
    Iliadis A; Brown AC; Huggins ML
    Comput Methods Programs Biomed; 1992 Aug; 38(4):227-39. PubMed ID: 1473342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Favereau JP; Gay R
    Int J Biomed Comput; 1994 Jun; 36(1-2):135-7. PubMed ID: 7927853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation.
    Lacarelle B; Pisano P; Gauthier T; Villard PH; Guder F; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):127-30. PubMed ID: 7927851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
    Cupissol D; Brès J; Gestin-Boyer C; Nouguier-Soulé J; Vian L; Tep A; Nouguier J
    Bull Cancer; 1996 Aug; 83(8):664-76. PubMed ID: 8869047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in strategies for dosage regimen individualization.
    Marouani H; Woloch C; Benay S; Frances N; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1669-77. PubMed ID: 22978335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients.
    Gauthier T; Lacarelle B; Marre F; Villard PH; Catalin J; Durand A
    Int J Biomed Comput; 1994 Jun; 36(1-2):131-4. PubMed ID: 7927852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin.
    Garraffo R; Iliadis A; Cano JP; Dellamonica P; Lapalus P
    J Pharm Sci; 1989 Sep; 78(9):753-7. PubMed ID: 2585270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
    Gomeni R; Pineau G; Mentré F
    Anticancer Res; 1994; 14(6A):2321-6. PubMed ID: 7825966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.
    Proost JH; Meijer DK
    Comput Biol Med; 1992 May; 22(3):155-63. PubMed ID: 1617949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.
    Proost JH
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):531-6. PubMed ID: 8574501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
    Labaune JM; Bleyzac N; Maire P; Jelliffe RW; Boutroy MJ; Aulagner G; Putet G
    Biol Neonate; 2001 Aug; 80(2):142-7. PubMed ID: 11509814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Gay C; Favereau JP; Gay R
    Eur J Clin Pharmacol; 1992; 43(4):435-6. PubMed ID: 1451727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of once-daily amikacin in elderly patients.
    Vanhaeverbeek M; Siska G; Herchuelz A
    J Antimicrob Chemother; 1993 Jan; 31(1):185-7. PubMed ID: 8444669
    [No Abstract]   [Full Text] [Related]  

  • 15. Benchmarking therapeutic drug monitoring software: a review of available computer tools.
    Fuchs A; Csajka C; Thoma Y; Buclin T; Widmer N
    Clin Pharmacokinet; 2013 Jan; 52(1):9-22. PubMed ID: 23196713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.
    Zaske DE; Cipolle RJ; Rotschafer JC; Kohls PR; Strate RG
    Ther Drug Monit; 1991 Nov; 13(6):502-6. PubMed ID: 1771647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.